THE FUTURE OF HIV CARE - LONG TERM REMISSION AND ELIMINATING CO-MORBIDITIES
Grant number: 1135851 | Funding period: 2018 - 2022
Despite the great successes in antiretroviral therapy (ART) in reducing HIV-associated mortality, treatment is life long and there is no cure. The major barrier to a cure for HIV is the persistence of long lived latently infected cells on ART. Over the next five years I will discover, develop, optimise and evaluate novel interventions to eliminate latently infected cells, long lived infected cells in the liver and enhance HIV-specific immunity through immunotherapy.
Related publications (6)
Integrated immune dynamics define correlates of COVID-19 severity and antibody responses
Marios Koutsakos, Louise C Rowntree, Luca Hensen, Brendon Y Chua, Carolien E van de Sandt, Jennifer R Habel, Wuji Zhang, Xiaoxiao Jia, Lukasz Kedzierski, Thomas M Ashhurst, Givanna H Putri, Felix Marsh-Wakefield, Mark N Read, Davis N Edwards, E Bridie Clemens, Chinn Yi Wong, Francesca L Mordant, Jennifer A Juno, Fatima Amanat, Jennifer Audsley
SARS-CoV-2 causes a spectrum of COVID-19 disease, the immunological basis of which remains ill defined. We analyzed 85 SARS-CoV-2-..
Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection
Kasha P Singh, Jennifer M Zerbato, Wei Zhao, Sabine Braat, Claire Deleage, G Surekha Tennakoon, Hugh Mason, Ashanti Dantanarayana, Ajantha Rhodes, Jake W Rhodes, Joe Torresi, Andrew N Harman, Peter A Revill, Megan Crane, Jacob D Estes, Anchalee Avihingsanon, Sharon R Lewin, Jennifer Audsley
In HIV-hepatitis B virus (HBV) co-infection, adverse liver outcomes including liver fibrosis occur at higher frequency than in HBV..
Longitudinal analysis of subtype C envelope tropism for memory CD4( )T cell subsets over the first 3 years of untreated HIV-1 infection
Matthew J Gartner, Paul R Gorry, Carolin Tumpach, Jingling Zhou, Ashanti Dantanarayana, J Judy Chang, Thomas A Angelovich, Paula Ellenberg, Annemarie E Laumaea, Molati Nonyane, Penny L Moore, Sharon R Lewin, Melissa J Churchill, Jacqueline K Flynn, Michael Roche
BACKGROUND: HIV-1 infects a wide range of CD4+ T cells with different phenotypic properties and differing expression levels of ent..
A gathering storm: HIV infection and nonalcoholic fatty liver disease in low and middle-income countries
Nitin Kapoor, Jennifer Audsley, Priscilla Rupali, Joe Sasadeusz, Thomas Paul, Nihal Thomas, Sharon R Lewin
: Despite the decreasing total incidence of liver-related deaths, liver disease remains one of the major non-AIDS causes of morbid..
HIV latency reversing agents act through Tat post translational modifications
Georges Khoury, Talia M Mota, Shuang Li, Carolin Tumpach, Michelle Y Lee, Jonathan Jacobson, Leigh Harty, Jenny L Anderson, Sharon R Lewin, Damian FJ Purcell
BACKGROUND: Different classes of latency reversing agents (LRAs) are being evaluated to measure their effects in reactivating HIV ..
HIV cure research: print and online media reporting in Australia
Jennifer Power, Bianca Fileborn, Gary W Dowsett, Jayne Lucke, Graham Brown, Jeanne Ellard, Sharon R Lewin, Joseph D Tucker, Sean Slavin, Jeremy Sugarman, Sophie Hill
OBJECTIVES: While still in its early stages, recent scientific research towards a cure for HIV has generated widespread media inte..